Lupin awarded USFDA approval for generic Lidex Ointment
DSIJ Intelligence / 02 Aug 2017
Pharmaceutical major Lupin has announced that it has received final approval for its Fluocinonide Topical Ointment USP, 0.05% from the USFDA to market a generic version of Country Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%.
Pharmaceutical major Lupin has announced that it has received final approval for its Fluocinonide Topical Ointment USP, 0.05% from the USFDA to market a generic version of Country Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%.
Lupin’s Fluocinonide Topical Ointment USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, said the company in a BSE filing on Tuesday.
Lidex Ointment had US sales of USD 40.3 million (IMS MAT March 2017).
Lupin was trading at Rs 1,033.50, up by Rs 15.50 or 1.52% as at 0945 hours on Wednesday, on the BSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.